Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Human Genetics Research Initiative to Accelerate Drug Discovery, Development

By Doris Mendieta
Posted on 27 Jan 2014
A new collaboration of a pharmaceutical company and health system in the United States has been established with the goal of enhancing patient care and accelerating new drug discovery and developments.

Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, USA) and Geisinger Health System (Danville, PA, USA), one of the largest integrated health systems in the United States, serving approximately 3 million residents, announced a major research collaboration geared on investigating the genetic determinants of human disease.

The new research initiative will include one of the largest United States populations of participants for the analysis and sequencing of genetic material and comparison to long-term health outcomes. During the initial five-year collaboration term, Geisinger plans to gather samples from more than 100,000 consented patient volunteers, while Regeneron, through its wholly-owned subsidiary, Regeneron Genetics Center, LLC, will perform sequencing and genotyping to generate de-identified genomic data. The size and extent of the study should allow great precision in identifying and confirmed the associations between genes and human disease.

The collaboration will benefit from Geisinger’s advanced sample collection and storage capabilities, the MyCode biorepository, and extensive electronic medical records. Regeneron has built an infrastructure to support sequencing and genotyping over the term of the collaboration. Regeneron intends to use its translational research and functional biology capabilities, including its VelociGene technology, to validate observed human genetic associations. “We are pleased to be embarking on this next generation human genetic sequencing project with Geisinger, a renowned integrated health care delivery system known for its innovation,” said Leonard S. Schleifer, MD, PhD, president and chief executive officer of Regeneron.

Next-generation DNA sequencing technology is enabling genetic research on a larger level was previously possible. The Regeneron-Geisinger genomics sequencing study is designed to utilize de-identified, clinical, and molecular data for medically significant associations in a blinded way that preserves patients’ privacy. The objective of the collaboration is to build a high-throughput platform for discovering and validating genetic factors that cause or influence a range of diseases where there are major unmet medical needs.

Regeneron is a science-based biopharmaceutical company that discovers, invents, develops, manufactures, and markets agents for the treatment of serious medical disorders. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition, and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis.

Geisinger Health System is an integrated health services organization known for its innovative use of the electronic health record (EHR) and the development of innovative care models such as ProvenHealth Navigator and ProvenCare. GHS serves more than 3 million residents throughout 44 counties in central and northeastern Pennsylvania.

Related Links:

Regeneron Pharmaceuticals
Geisinger Health System



comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.